tiprankstipranks
Advertisement
Advertisement
Entera Bio Submits Streamlined Phase 3 Plan for EB613
PremiumCompany AnnouncementsEntera Bio Submits Streamlined Phase 3 Plan for EB613
1M ago
Entera Bio submits streamlined Phase 3 protocol to U.S. FDA for EB613
Premium
The Fly
Entera Bio submits streamlined Phase 3 protocol to U.S. FDA for EB613
1M ago
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woman Osteoporosis Market (NASDAQ: ENTX)
Premium
TipRanks Newswire
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woman Osteoporosis Market (NASDAQ: ENTX)
2M ago
Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet
PremiumThe FlyOpko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet
2M ago
Entera Bio announces expected milestones for Q1 in 2026
Premium
The Fly
Entera Bio announces expected milestones for Q1 in 2026
3M ago
Entera Bio ‘congratulates’ FNIH-ASBMR-SABRE team on FDA endpoint qualification
Premium
The Fly
Entera Bio ‘congratulates’ FNIH-ASBMR-SABRE team on FDA endpoint qualification
4M ago
Entera Bio’s Promising Oral Therapies Drive Buy Rating: Analyst Highlights Developments in GLP-2 and EB613 Programs
PremiumRatingsEntera Bio’s Promising Oral Therapies Drive Buy Rating: Analyst Highlights Developments in GLP-2 and EB613 Programs
7M ago
Entera Bio announces presentation of PK data for GLP-2 tablet treatment
Premium
The Fly
Entera Bio announces presentation of PK data for GLP-2 tablet treatment
7M ago
Entera Bio presents data on EB613 in post-menopausal women with osteoporosis
Premium
The Fly
Entera Bio presents data on EB613 in post-menopausal women with osteoporosis
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100